Kymera Therapeutics (KYMR) Competitors $49.13 -2.03 (-3.97%) Closing price 09/19/2025 04:00 PM EasternExtended Trading$49.72 +0.59 (+1.20%) As of 09/19/2025 07:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock KYMR vs. RDY, ASND, VTRS, QGEN, BBIO, ROIV, ELAN, MRNA, VRNA, and RVMDShould you be buying Kymera Therapeutics stock or one of its competitors? The main competitors of Kymera Therapeutics include Dr. Reddy's Laboratories (RDY), Ascendis Pharma A/S (ASND), Viatris (VTRS), Qiagen (QGEN), BridgeBio Pharma (BBIO), Roivant Sciences (ROIV), Elanco Animal Health (ELAN), Moderna (MRNA), Verona Pharma PLC American Depositary Share (VRNA), and Revolution Medicines (RVMD). These companies are all part of the "pharmaceutical products" industry. Kymera Therapeutics vs. Its Competitors Dr. Reddy's Laboratories Ascendis Pharma A/S Viatris Qiagen BridgeBio Pharma Roivant Sciences Elanco Animal Health Moderna Verona Pharma PLC American Depositary Share Revolution Medicines Dr. Reddy's Laboratories (NYSE:RDY) and Kymera Therapeutics (NASDAQ:KYMR) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, profitability, risk, analyst recommendations, dividends and media sentiment. Do institutionals & insiders have more ownership in RDY or KYMR? 3.9% of Dr. Reddy's Laboratories shares are owned by institutional investors. 2.0% of Dr. Reddy's Laboratories shares are owned by company insiders. Comparatively, 16.0% of Kymera Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Is RDY or KYMR more profitable? Dr. Reddy's Laboratories has a net margin of 16.99% compared to Kymera Therapeutics' net margin of -616.03%. Dr. Reddy's Laboratories' return on equity of 17.25% beat Kymera Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Dr. Reddy's Laboratories16.99% 17.25% 11.63% Kymera Therapeutics -616.03%-31.60%-27.12% Does the media prefer RDY or KYMR? In the previous week, Kymera Therapeutics had 22 more articles in the media than Dr. Reddy's Laboratories. MarketBeat recorded 29 mentions for Kymera Therapeutics and 7 mentions for Dr. Reddy's Laboratories. Dr. Reddy's Laboratories' average media sentiment score of 1.08 beat Kymera Therapeutics' score of 0.47 indicating that Dr. Reddy's Laboratories is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dr. Reddy's Laboratories 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Kymera Therapeutics 6 Very Positive mention(s) 4 Positive mention(s) 8 Neutral mention(s) 4 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more volatility & risk, RDY or KYMR? Dr. Reddy's Laboratories has a beta of 0.32, suggesting that its share price is 68% less volatile than the S&P 500. Comparatively, Kymera Therapeutics has a beta of 2.17, suggesting that its share price is 117% more volatile than the S&P 500. Which has higher earnings & valuation, RDY or KYMR? Dr. Reddy's Laboratories has higher revenue and earnings than Kymera Therapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than Dr. Reddy's Laboratories, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDr. Reddy's Laboratories$3.81B3.26$663M$0.6622.52Kymera Therapeutics$47.07M74.63-$223.86M-$3.47-14.16 Do analysts recommend RDY or KYMR? Dr. Reddy's Laboratories currently has a consensus price target of $16.95, indicating a potential upside of 14.06%. Kymera Therapeutics has a consensus price target of $59.95, indicating a potential upside of 22.02%. Given Kymera Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Kymera Therapeutics is more favorable than Dr. Reddy's Laboratories.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dr. Reddy's Laboratories 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.80Kymera Therapeutics 0 Sell rating(s) 1 Hold rating(s) 17 Buy rating(s) 2 Strong Buy rating(s) 3.05 SummaryDr. Reddy's Laboratories beats Kymera Therapeutics on 9 of the 17 factors compared between the two stocks. Get Kymera Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KYMR and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding KYMR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KYMR vs. The Competition Export to ExcelMetricKymera TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.66B$3.15B$5.80B$10.40BDividend YieldN/A2.37%5.63%4.60%P/E Ratio-14.1620.9180.4326.78Price / Sales74.63448.41534.66123.54Price / CashN/A46.6037.9961.55Price / Book3.819.6615.776.40Net Income-$223.86M-$53.22M$3.30B$271.80M7 Day Performance4.55%3.11%5.37%3.48%1 Month Performance16.01%7.56%8.10%9.89%1 Year Performance-1.33%11.15%81.36%28.44% Kymera Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KYMRKymera Therapeutics2.1872 of 5 stars$49.13-4.0%$59.95+22.0%+0.2%$3.66B$47.07M-14.16170Trending NewsAnalyst ForecastInsider TradeAnalyst RevisionHigh Trading VolumeRDYDr. Reddy's Laboratories2.6773 of 5 stars$14.64-0.2%$16.95+15.8%-5.2%$12.24B$3.81B22.1727,811Positive NewsASNDAscendis Pharma A/S2.7317 of 5 stars$194.62-0.5%$244.36+25.6%+28.8%$11.97B$393.54M-37.721,017VTRSViatris1.1288 of 5 stars$9.60-3.6%$10.40+8.3%-16.8%$11.61B$14.74B-3.3132,000High Trading VolumeQGENQiagen4.4565 of 5 stars$45.39+0.2%$49.69+9.5%+3.7%$10.07B$2.04B26.825,765BBIOBridgeBio Pharma4.3316 of 5 stars$51.47+0.5%$63.94+24.2%+95.2%$9.79B$235.81M-12.58400ROIVRoivant Sciences3.4495 of 5 stars$13.95-0.9%$17.67+26.6%+26.2%$9.61B$29.05M-19.93860Trending NewsAnalyst ForecastAnalyst RevisionELANElanco Animal Health2.8063 of 5 stars$18.63+0.5%$17.33-6.9%+27.3%$9.21B$4.48B21.669,000MRNAModerna4.4715 of 5 stars$23.88+1.6%$41.81+75.1%-62.9%$9.15B$3.06B-3.175,800VRNAVerona Pharma PLC American Depositary Share2.0949 of 5 stars$106.37-0.1%$109.00+2.5%+260.6%$8.71B$221.67M-107.4430Positive NewsRVMDRevolution Medicines4.2574 of 5 stars$46.20-0.8%$73.67+59.5%-5.7%$8.70BN/A-10.27250Trending NewsInsider Trade Related Companies and Tools Related Companies RDY Competitors ASND Competitors VTRS Competitors QGEN Competitors BBIO Competitors ROIV Competitors ELAN Competitors MRNA Competitors VRNA Competitors RVMD Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KYMR) was last updated on 9/20/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredNvidia CEO Makes First Ever Tesla AnnouncementWhile headlines focus on Tesla’s car sales, tech analyst Jeff Brown says the real story is Tesla’s role in a $...Brownstone Research | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredCollege grad makes $64,000 a monthA Wall Street legend just helped train our own proprietary AI system in the stock market (a project that took ...Stansberry Research | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kymera Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kymera Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
